N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation.

N6-Methyladenosine (m6A) on mRNAs mediates different biological processes and its dysregulation contributes to tumorigenesis. How m6A dictates its diverse molecular and cellular effects in leukemias remains unknown. We found that YTHDC1 is the essential m6A reader in myeloid leukemia from a genome-wide CRISPR screen and that m6A is required for ...
YTHDC1 to undergo liquid-liquid phase separation and form nuclear YTHDC1-m6A condensates (nYACs). The number of nYACs increases in acute myeloid leukemia (AML) cells compared with normal hematopoietic stem and progenitor cells. AML cells require the nYACs to maintain cell survival and the undifferentiated state that is critical for leukemia maintenance. Furthermore, nYACs enable YTHDC1 to protect m6A-mRNAs from the PAXT complex and exosome-associated RNA degradation. Collectively, m6A is required for the formation of a nuclear body mediated by phase separation that maintains mRNA stability and control cancer cell survival and differentiation.
Mesh Terms:
Adenosine, Animals, Apoptosis, Cell Differentiation, Cell Nucleus, Cell Proliferation, DNA Methylation, Female, Hematopoiesis, Humans, Leukemia, Myeloid, Acute, Liquid-Liquid Extraction, Mice, Mice, Inbred NOD, Mice, SCID, Nerve Tissue Proteins, Phase Transition, Proto-Oncogene Proteins c-myc, RNA Splicing Factors, RNA Stability, RNA, Messenger, Tumor Cells, Cultured, Xenograft Model Antitumor Assays
Cancer Cell
Date: Dec. 12, 2020
Download Curated Data For This Publication
234805
Switch View:
  • Interactions 216